3O5X

Crystal structure of the oncogenic tyrosine phosphatase SHP2 complexed with a salicylic acid-based small molecule inhibitor

Replaces:  3JRL

Summary for 3O5X

• Entry DOI: 10.2210/pdb3o5x/pdb
• Related: 3JRL
• Descriptor: Tyrosine-protein phosphatase non-receptor type 11, 3-{1-[3-(biphenyl-4-ylamino)-3-oxopropyl]-1H-1,2,3-triazol-4-yl}-6-hydroxy-1-methyl-2-phenyl-1H-indole-5-carboxylic acid (3 entities in total)
• Functional Keywords: shp2-iib-08 complex, inhibitor, binding affinity, binding selectivity, receptor, hydrolase, dephosphorylation
• Biological source: Homo sapiens (human)
• Cellular location: Cytoplasm: Q06124
• Total number of polymer chains: 1
• Total formula weight: 32835.30

Authors

Zhang, Z.-Y.,Zhang, X.,He, Y.,Liu, S.,Yu, Z.,Jiang, Z.,Yang, Z.,Dong, Y.,Nabinger, S.C.,Wu, L.,Gunawan, A.M.,Wang, L.,Chan, R.J. (deposition date: 2010-07-28, release date: 2010-08-11, Last modification date: 2023-09-06)

Primary citation

Zhang, X.,He, Y.,Liu, S.,Yu, Z.,Jiang, Z.X.,Yang, Z.,Dong, Y.,Nabinger, S.C.,Wu, L.,Gunawan, A.M.,Wang, L.,Chan, R.J.,Zhang, Z.Y.
Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).
J.Med.Chem., 53:2482-2493, 2010

PubMed Abstract: The Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) plays a pivotal role in growth factor and cytokine signaling. Gain-of-function SHP2 mutations are associated with Noonan syndrome, various kinds of leukemias, and solid tumors. Thus, there is considerable interest in SHP2 as a potential target for anticancer and antileukemia therapy. We report a salicylic acid based combinatorial library approach aimed at binding both active site and unique nearby subpockets for enhanced affinity and selectivity. Screening of the library led to the identification of a SHP2 inhibitor II-B08 (compound 9) with highly efficacious cellular activity. Compound 9 blocks growth factor stimulated ERK1/2 activation and hematopoietic progenitor proliferation, providing supporting evidence that chemical inhibition of SHP2 may be therapeutically useful for anticancer and antileukemia treatment. X-ray crystallographic analysis of the structure of SHP2 in complex with 9 reveals molecular determinants that can be exploited for the acquisition of more potent and selective SHP2 inhibitors.

PubMed: 20170098
DOI: 10.1021/jm901645u

Experimental method

X-RAY DIFFRACTION (2 Å)